Business Context and Reporting Period
Company: ProQR Therapeutics N.V.
Filing Type: Form 20-F (Annual Report)
Reporting Period: Fiscal year ended December 31, 2016
Business Overview: ProQR is a clinical-stage biopharmaceutical company developing RNA-based therapeutics for severe genetic rare diseases. The company has no approved products and has not generated product revenue. Its primary focus is on three lead programs: QR-010 for Cystic Fibrosis (CF), QR-110 for Leber's Congenital Amaurosis (LCA), and QR-313 for Dystrophic Epidermolysis Bullosa (DEB). The company is incorporated in the Netherlands and lists on the NASDAQ Global Market.
Key Financial Metrics
| Metric (€ in thousands) | 2016 | 2015 | 2014 |
|---|---|---|---|
| Other Income | 1,828 | 3,235 | 313 |
| Research & Development Costs | (31,923) | (23,401) | (10,267) |
| General & Administrative Costs | (9,478) | (6,837) | (6,507) |
| Operating Result | (39,573) | (27,003) | (16,461) |
| Net Loss | (39,103) | (20,832) | (12,127) |
| Cash and Cash Equivalents (Year End) | 59,200 | 94,865 | 112,736 |
| Total Assets | 65,543 | 100,109 | 115,247 |
| Total Liabilities | 12,407 | 10,310 | 5,843 |
| Shareholders' Equity | 53,136 | 89,799 | 109,404 |
| Accumulated Deficit | (75,733) | — | — |
Note: Financial statements are prepared in accordance with IFRS. The filing does not provide specific margin percentages as the company has no revenue.
Material Changes vs. Prior Period
- Increased Net Loss: Net loss more than doubled from €20.8 million in 2015 to €39.1 million in 2016. This was driven primarily by a 36% increase in R&D expenses and a 39% increase in G&A expenses.
- R&D Expense Growth: R&D costs rose to €31.9 million in 2016 from €23.4 million in 2015. Increases were attributed to clinical trial costs for QR-010, increased staff (R&D FTEs grew from 72 to 100), and costs for GMP compound production.
- Cash Burn: Cash and cash equivalents decreased by approximately €35.7 million during 2016, ending the year at €59.2 million. Net cash used in operating activities was €34.2 million.
- Finance Income Decline: Net finance income dropped significantly from €6.2 million in 2015 to €0.5 million in 2016, largely due to reduced foreign exchange benefits on U.S. dollar-denominated cash balances compared to the prior year.
Guidance, Outlook, and Risks
Outlook and Liquidity
Management expects to continue incurring significant losses for the foreseeable future. Based on the current operating plan and cash balance of €59.2 million as of December 31, 2016, the company believes it has sufficient resources to fund operations through mid-2018. The company anticipates no product revenue in the foreseeable future.
Key Milestones and Programs
- QR-010 (CF): Positive proof-of-concept data was presented in October 2016. A Phase 1b safety trial is ongoing, with top-line data expected in mid-2017. A Phase 2 trial is planned for 2018.
- QR-110 (LCA): Expected to enter clinical trials in the first half of 2017.
- QR-313 (DEB): Expected to enter clinical trials in 2018.
Material Risks and Contingencies
- Capital Needs: The company will require additional capital to fund operations beyond mid-2018. Failure to secure financing could force delays or discontinuation of programs.
- Commercial Milestone Obligation: The first commercial sale of QR-010 will trigger a milestone payment of approximately $80 million to the Cystic Fibrosis Foundation Therapeutics (CFFT). The company notes it may not have sufficient funds to support this payment upon approval.
- Regulatory and Clinical Risk: As a clinical-stage company, there is a high risk of failure in clinical trials or regulatory approval. The company relies on third-party manufacturers and CROs.
- Intellectual Property: The company relies on licensed IP from third parties (e.g., MGH, Radboud University). Failure to meet milestones or defend patents could result in loss of rights.
- PFIC Status: The company believes it may be classified as a Passive Foreign Investment Company (PFIC) for U.S. tax purposes, which could have adverse tax consequences for U.S. shareholders.
Investor Verification Checklist
- Cash Runway: Verify the accuracy of the "mid-2018" liquidity estimate given the high burn rate (€34.2M operating cash outflow in 2016).
- CFFT Milestone: Assess the company's strategy for funding the potential $80 million milestone payment to CFFT upon the first commercial sale of QR-010.
- Clinical Data: Monitor the release of top-line data from the QR-010 Phase 1b trial (expected mid-2017) and the initiation of the QR-110 trial.
- Financing Plans: Review any upcoming equity offerings or debt financings required to extend the runway beyond 2018, noting potential dilution.
- IP Dependencies: Confirm the status of key license agreements with MGH and Radboud University, specifically regarding milestone payments and diligence obligations.